by Alyssa Lee | Aug 14, 2025
DelRicht Research is proud to highlight the exceptional performance of our investigators and site teams in a US-based Phase 2 trial for diarrhea-predominant irritable bowel syndrome (IBS-D). Over an ambitious 19-month enrollment period, our network not only exceeded...
by Alyssa Lee | Aug 1, 2025
As vaccine development continues to evolve in complexity and urgency, DelRicht Research stands out as a high-performing site network delivering results across infectious disease studies. With over 16 vaccine trials completed in the past five years and 10,000+...
by Alyssa Lee | May 1, 2025
DelRicht Research is pleased to highlight the strong performance of our site teams in a Phase 4 clinical trial focused on major depressive disorder (MDD) in adults aged 18-65. Over an 18-month enrollment period, our network surpassed expectations, delivering results...
by Nicole Caravella | Apr 30, 2025
The U.S. Food and Drug Administration has approved Atzumi™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults. Developed by Satsuma Pharmaceuticals, Atzumi™ is the first and only DHE nasal powder to receive FDA...
by Alyssa Lee | Nov 1, 2024
DelRicht Research is proud to share the remarkable performance of our site team in a Phase 3 clinical trial investigating therapies for major depressive disorder (MDD) in adults ages 18-65. Within a condensed eight-month enrollment window, our site reached its target...
